Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Newron Pharmaceuticals SpA logo — The Specialist in CNS Drug Development

Newron Pharmaceuticals SpA

The Specialist in CNS Drug Development

Founded 1999 Italy Italy 23 employees Post Ipo Equity Total: $129.36M Biopharma, Biotechnology +1

General Information

Company Name Newron Pharmaceuticals SpA
Founded Year 1999
Location Italy Italy +1
Employees 23
Industries Biopharma, Biotechnology, Health Care
Funding Stage Post Ipo Equity
Social

Get notified when Newron Pharmaceuticals SpA moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Newron Pharmaceuticals SpA

Newron Pharmaceuticals is a biopharmaceutical company headquartered in Italy, with a subsidiary in the USA. The company, founded in 1999, specializes in developing novel therapies for diseases of the central nervous system (CNS) and pain. With a balanced and robust pipeline of drug candidates at different clinical stages, Newron has a proven track record of drug development and commercialization. One of its notable successes is the marketing authorization and commercialization of Xadago® (safinamide) for the treatment of Parkinson’s disease in various regions including the European Union, Switzerland, the US, and other markets. Additionally, the company has a promising pipeline of treatments including Evenamide as an add-on therapy for schizophrenia and ralfinamide for specific rare pain indications. In 2017, Newron raised a Fr.27.00M Post-IPO Equity investment. Despite not specifying the investors, this investment demonstrates continued interest and support for the company's innovative approaches in the biopharma, biotechnology, and health care industries. As a publicly listed company on the SIX Swiss Exchange, Düsseldorf Stock Exchange, and XETRA, Newron Pharmaceuticals continues to showcase a strong commitment to delivering innovative treatments to improve the quality of life for patients with CNS disorders.

Taxonomy: biopharmaceutical, CNS drug development, Parkinson's disease treatment, neurological disorders, rare diseases, pharmaceutical commercialization, clinical development, schizophrenia treatment, drug candidates, innovative therapies, SIX Swiss Exchange, European pharmaceutical companies, US pharmaceutical market, Neurological drug research, Italian biopharmaceutical companies

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 26 Sep 2017
Post-IPO Equity •••••• - 07 Oct 2016
Post-IPO Equity •••••• - 20 Nov 2015
Post-IPO Equity •••••• - 30 Apr 2015
Post-IPO Equity •••••• - 23 Aug 2012

View All 10 Funding Rounds

Newron Pharmaceuticals SpA Alternatives & Competitors

Newron Pharmaceuticals SpA vs
IRLAB Therapeutics AB
IRLAB Therapeutics AB Sweden

A clinical-stage biopharma discovering and developing novel treatments for the most troublesome symp...

Grant
37 employees
Health Care, Health and Wellness
Newron Pharmaceuticals SpA vs
Clexio Biosciences
Clexio Biosciences Israel

Making life worth living again for millions of patients

44 employees
Biotechnology, Health Care
Newron Pharmaceuticals SpA vs
Addex Therapeutics
Addex Therapeutics Switzerland

Allosteric modulators for Human Health

Post Ipo Equity
19 employees
Biotechnology, Health Care

FAQ About Newron Pharmaceuticals SpA

The Specialist in CNS Drug Development
Newron Pharmaceuticals SpA was founded in 1999.
Newron Pharmaceuticals SpA is headquartered in Italy.
Newron Pharmaceuticals SpA operates in the following industries: Biopharma, Biotechnology, Health Care.
Newron Pharmaceuticals SpA has approximately 23 employees.
Newron Pharmaceuticals SpA has completed 10 funding rounds, raising a total of $129.36M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Newron Pharmaceuticals SpA include IRLAB Therapeutics AB, Clexio Biosciences, Addex Therapeutics, MindMed, ConSynance Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Newron Pharmaceuticals SpA and IRLAB Therapeutics AB are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Newron Pharmaceuticals SpA and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy